In foreign countries,ascorbic acid (vitamin C) has been used as a complementary drug in cancer treatments for many years.Although it has not been accepted by mainstream medicine,a growing number of in vitro and in vivo experiments indicated that pharmacological concentrations of ascorbic acid could inhibited cancer cell proliferation and promote cell apoptosis.In this paper,the anti-cancer effect of ascorbic acid weer reviewe.d.

Dietary factors play important roles in the initiation and development of breast cancer. There are numerous articles on this topic and most of them focus on the associations between dietary fat, vegetable, fruit, alcohol, phytoestrogen intakes and breast cancer. Different conclusions have been reached.

Objective To observe the anti-tumor effect and mechanism of curcumin on triple-negative breast cancer mouse model.Methods Human breast cancer cells MDA-MB-231 were inoculated to the chest subcutaneous fat pad of mice(about 1 million cells in 0.1 mL cell suspension).At day 2 after tumor inoculation,nodules were seen at inoculation site (tumor formation rate being 100％).Forty successfully-modeled mice were randomly divided into low-,middle-,and high-dose curcumin groups (10,20,40 mg/kg) and model control group,10 mice in each group.The medication lasted for 30 continuous days.After medication,the blood was taken out from the orbital venous plexus,and the serum was separated for the detection of tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) contents.Spleen was separated for the calculation of organ coefficient,tumor mass was weighed,and the expression levels of Bcl-2 and caspase-3 were detected by Western blotting method.Results Compared with the model control group,caspase-3 expression level was significantly increased in the three curcumin groups(P ＜ 0.05 or P ＜ 0.01),but the contents of TNF-α and IL-6,tumor weight,spleen index and Bcl-2 expression were significantly decreased(P ＜ 0.05 or P ＜ 0.01).Conclusion Curcumin has inhibitory effect on triple-negative breast cancer mouse model through promoting the apoptosis of breast cancer cells.

An increasing number of evidence indicate that intravenous high-dose vitamin C (HVC) is safe to use in patients with various types of cancer. Clinical studies suggest that when used in combination with radiation and chemotherapy, HVC can reduce their toxic side effects and substantially prolong the overall survival of patients. In vitro and animal experiments demonstrated that vitamin C has pro-oxidant cytotoxicity, reverses epithelial-mesenchymal transition, inhibits hypoxia and oncogenic kinase signal transduction, and improves immune function. Although many phase Ⅰ/Ⅱ clinical studies and case reports confirming the adjuvant anti-tumor effects of HVC have been published, large-sample, multicenter randomized controlled phase Ⅲ clinical trial data are still lacking. Therefore, this paper further explores the role and significance of this low-toxicity adjuvant antitumor therapy in clinical use.